Hjem › Myasthenia gravis › New York
Myasthenia gravis kliniske forsøg i New York
13 studier for Myasthenia gravis søger deltagere på steder i New York.
Byer i New York
Officiel studietekst (engelsk)
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Mg0038 10106, Amherst
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07463521Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Equity Medical, New York
RekruttererFase 3
Alder 18 til 74 · Alle køn · Opdateret 25. sep. 2026 · NCT07217587ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Dent Neurologic Institute - Amherst, Amherst
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT07673627ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- Dent Neurologic Institute - Amherst, Amherst
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT07294170ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- Dent Neurologic Institute - Amherst, Amherst
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT07284420A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, New York
- TG Therapeutics Investigational Trial Site, Rochester
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT06680037A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
- Columbia University Irving Medical Center, New York
RekruttererFase 1
Alder 18 til 75 · Alle køn · Opdateret 14. aug. 2026 · NCT07304154RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
- Columbia University, New York
- University of Rochester Medical Center, Rochester
RekruttererFase 1/2
Alder 18 til 70 · Alle køn · Opdateret 13. aug. 2026 · NCT06359041Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1036, New York
- Site Number - 1034, New York
RekruttererFase 3
Alder 18 til 80 · Alle køn · Opdateret 30. jul. 2026 · NCT07039916A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- Hospital for Special Surgery, New York
- Mount Sinai Health System, New York
- Montefiore Medical Center, The Bronx
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 18. jun. 2026 · NCT06456580A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases
- Columbia University Irving Medical Center, New York
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 25. feb. 2026 · NCT06626919Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, New Hyde Park
RekruttererObservationsstudie
Alder 18 og opefter · Alle køn · Opdateret 18. feb. 2026 · NCT04202341The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
- Neurological Associates of Long Island, P.C., Lake Success
RekruttererFrivillige med god helbredstilstand velkomne
Alder 18 og opefter · Alle køn · Opdateret 11. apr. 2025 · NCT05564936Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.